Loading...
Should We Use PPAR Agonists to Reduce Cardiovascular Risk?
Trials of peroxisome proliferator-activated receptor (PPAR) agonists have shown mixed results for cardiovascular prevention. Fibrates are PPAR- [Formula: see text] agonists that act primarily to improve dyslipidemia. Based on low- and high-density lipoprotein cholesterol (LDL and HDL) effects, gemfi...
Saved in:
| Main Author: | |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Hindawi Publishing Corporation
2008
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2234387/ https://ncbi.nlm.nih.gov/pubmed/18288293 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2008/891425 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|